The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE trial final results.
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Takeshi Terashima
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tatsuya Yamashita
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Kyowa Kirin International; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Hiroshi Imaoka
Honoraria - AstraZeneca; Boston Scientific; Kaneka Medix; Medico's Hirata; Novartis; SB-KAWASUMI LABORATORIES; SERVIER; Yakult Honsha
Consulting or Advisory Role - SERVIER
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER
Expert Testimony - Kaneka Medix
 
Tomokazu Kawaoka
Research Funding - AstraZeneca; Roche
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; MSD; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zymeworks
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Sadahisa Ogasawara
Honoraria - AstraZeneca/Daiichi Sankyo; Chugai Pharma; Eisai; Merck
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Merck
Research Funding - AstraZeneca; Chugai Pharma; Eisai; Lilly
 
Atsushi Hiraoka
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly Japan
 
Masahito Nakano
No Relationships to Disclose
 
Fumio Nagashima
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Janssen; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Rie Sugimoto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai
 
Michihisa Moriguchi
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly Japan; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst)
 
Yoshitaka Inaba
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Eisai (Inst)
 
Satoru Shinoda
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoya Kato
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; J-Pharma; MSD; Novartis; Ohara Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; J-Pharma; MSD; OncoTherapy Science
 
Hiroaki Nagano
No Relationships to Disclose